Myriad Genetics, Inc. (NASDAQ:MYGN)
CAPS Rating:
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
Growing the love for investing
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Well run company with minimal debt. All star board of directors. The future will eventually be preventative medicine, and this company is an early mover in that field.